FDA officials said in a NEJM article that curtailing their requirement for a median of two months of safety follow-up could undermine its scientific credibility. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
